Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (132)
  • Open Access

    ARTICLE

    OTUB2 promotes proliferation and metastasis of triple-negative breast cancer by deubiquitinating TRAF6

    YU QIU1,#, RUIHAN LIU2,#, SHANSHAN HUANG1, QIAOTING CAI1, YI XIE1, ZHITING HE1, WEIGE TAN2,*, XINHUA XIE1,*

    Oncology Research, Vol.33, No.5, pp. 1135-1147, 2025, DOI:10.32604/or.2025.062767 - 18 April 2025

    Abstract Objectives: Deubiquitinase OTUB2 plays a critical role in the progression of various tumors. However, its specific role in triple-negative breast cancer (TNBC) remains unclear. This study aims to elucidate the biological function of OTUB2 in TNBC and uncover the underlying mechanisms. Methods: First, we found that the expression of OTUB2 was upregulated in TNBC by bioinformatics analysis, we then validated its expression in TNBC tissues and cells using immunohistochemistry (IHC) and qPCR and plotted the survival curves by Kaplan-Meier method. Gene set enrichment analysis (GSEA) suggested that OTUB2 may be involved in tumor proliferation and metastasis.… More > Graphic Abstract

    OTUB2 promotes proliferation and metastasis of triple-negative breast cancer by deubiquitinating TRAF6

  • Open Access

    REVIEW

    Promising roles of vitamin D receptor and APRO family proteins for the development of cancer stem cells targeted malignant tumor therapy

    MOEKA NAKASHIMA, NAOKO SUGA, AKARI FUKUMOTO, SAYURI YOSHIKAWA, SATORU MATSUDA*

    Oncology Research, Vol.33, No.5, pp. 1007-1017, 2025, DOI:10.32604/or.2025.059657 - 18 April 2025

    Abstract Malignant tumors are heterogeneous diseases characterized by uncontrolled cell proliferation, invasion, metastasis, and/or recurrence of their malignancies. In particular, cancer stem cells (CSCs) within these tumors might be responsible for the property of invasiveness and/or therapies-resistance. CSCs are a self-renewing, awfully tumorigenic subpopulation of cancer cells, which are notorious for strong chemoresistance and are frequently responsible the aggravated invasion, metastasis, and/or recurrence. Developing targeting therapies against CSCs, therefore, may be deliberated a more encouraging mission for the greater cancer therapy. Innovation for a more potent anti-CSC treatment has been required as soon as possible.… More > Graphic Abstract

    Promising roles of vitamin D receptor and APRO family proteins for the development of cancer stem cells targeted malignant tumor therapy

  • Open Access

    ARTICLE

    A novel Wnt/β-catenin signaling gene signature for progression and metastasis of gastric cancer

    JIA CHEN1,2, FEI JIANG1, KAIYI NIU3, HAODONG ZHAO2, LI LI1,*, HONGZHU YU1,*

    Oncology Research, Vol.33, No.5, pp. 1199-1215, 2025, DOI:10.32604/or.2024.054366 - 18 April 2025

    Abstract Backgrounds: As cancer progresses through various stages of malignancy, metastasis, and drug resistance, the Wnt/-catenin signaling is frequently dysregulated. Despite advancements in medical technology and therapeutic strategies, the prognosis for numerous gastric cancer patients remains unfavorable. Methods: For the analysis of prognostic signature genes associated with Wnt signaling in GC, we used LASSO (least absolute shrinkage and selection operator) regression. To explore the function, cell specificity, and transcriptional regulation of the signature gene Carboxypeptidase Z (CPZ), we conducted co-expression analysis, single-cell RNA sequencing data analysis, transcription factor prediction, and dual luciferase reporter assay. The knockdown… More >

  • Open Access

    CASE REPORT

    Perivascular epithelioid cell neoplasm of the bladder with peritoneal metastasis

    Peter J. Arnold1,*, Mabel Spio2, Reem Youssef3, Carina Dehner3, Kevin Rice1

    Canadian Journal of Urology, Vol.32, No.1, pp. 47-53, 2025, DOI:10.32604/cju.2025.064694 - 20 March 2025

    Abstract Perivascular epithelioid cell tumors (PEComas) are a diverse group of mesenchymal neoplasms. While they have been described throughout the genitourinary system, PEComas are quite rare within the bladder. We present the case of a 37-year-old male who presented in clot retention and was found to have a bladder PEComa. Staging images seemingly demonstrated solid tumor confinement to the bladder and pelvis. Intraoperative pathology revealed peritoneal metastasis. The patient underwent a pelvic mass excision and partial cystectomy. The patient had plans for adjuvant chemotherapy, but later returned to the hospital and passed away from acute hypoxic More >

  • Open Access

    ARTICLE

    A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer

    JIYUN PANG1,2,#, WEIGANG XIU1,#, YUEYUN CHEN4, WENJING LIAO1,2, QIN ZHANG3,*, HUASHAN SHI4,*

    Oncology Research, Vol.33, No.4, pp. 895-904, 2025, DOI:10.32604/or.2024.053363 - 19 March 2025

    Abstract Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable… More >

  • Open Access

    ARTICLE

    Evaluating the efficacy and safety of Anlotinib in conjunction with stereotactic radiosurgery for small cell lung cancer patients with brain metastases

    LIZHI WANG1, HUILIN SUN2, GUIZHI YU1, ZEJING QU1, YING JI1, YANPING CUI1,*

    Oncology Research, Vol.33, No.4, pp. 885-894, 2025, DOI:10.32604/or.2024.051586 - 19 March 2025

    Abstract Background: Small cell lung cancer (SCLC) is characterized by its aggressive nature and high propensity for brain metastases. This study investigates the clinical efficacy and safety profile of Anlotinib in combination with Stereotactic Radiotherapy (SRT) for treating brain metastases in patients with small cell lung cancer (SCLC). Methods: This research included 98 SCLC brain metastasis patients treated at Chengde Central Hospital from October 2020 to January 2024. The patients were categorized into a combined treatment group (CTG) (n = 45) and a Simple SRT group (SSG)(n = 53). The CTG (58 lesions) received Anlotinib with… More >

  • Open Access

    ARTICLE

    Preventive effects of low-dose radiation and hypofractionated radiation plus anti-programmed cell death protein 1 on lung metastasis in breast cancer

    SHUANG CHEN1,2,#, XUEMEI DENG2,#, XINGTING HE2, KEWEI XIANG2, GUIHONG CHEN2, HONGRU YANG2,*

    Oncology Research, Vol.33, No.3, pp. 687-694, 2025, DOI:10.32604/or.2024.052133 - 28 February 2025

    Abstract Background: Previous experiments have demonstrated that hypofractionated radiation therapy (HFRT), low-dose radiation therapy (LDRT), and combined anti-programmed cell death protein 1 (αPD-1) can enhance the abscopal effect. Combined with the phenomenon of low prognosis in patients with breast cancer lung metastasis, our study establishes a mouse model and changes the irradiation regimen of LDRT to explore its preventive effect on breast cancer lung metastasis. Methods: The breast cancer subcutaneous graft tumor model was developed. Two-lung prophylactic LDRT was performed prior to the onset of lung metastases, in combination with HFRT (8 Gy, 3f), and αPD-1… More >

  • Open Access

    ARTICLE

    EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway

    NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI*

    Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

    Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

  • Open Access

    ARTICLE

    Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer

    ZHENGYANG ZHOU1,#, LEI QIAO1,#, TONGTONG WANG1, WEN PAN1, JINGJING DUAN1, HAIYANG ZHANG2, TING DENG1, YI BA1,*, YI HE1,*

    Oncology Research, Vol.33, No.2, pp. 327-345, 2025, DOI:10.32604/or.2024.050431 - 16 January 2025

    Abstract Background: Patients with gastric cancer (GC) are prone to lymph node metastasis (LNM), which is an important factor for recurrence and poor prognosis of GC. Nowadays, more and more studies have confirmed that exosomes can participate in tumor lymphangiogenesis. An in-depth exploration of the pathological mechanism in the process of LNM in GC may provide effective targets and improve the diagnosis and treatment effect. Materials and Methods: We used sequencing analysis of collected serum to screen out exo-miRNA related to LNM in GC. ELISA, qRT-PCR, Western Blot, RNA pull-down assay, Transwell assay, animal experiments, and other… More > Graphic Abstract

    Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer

  • Open Access

    RETRACTION

    Retraction: Long noncoding RNA urothelial carcinoma-associated 1 promotes the proliferation and metastasis of human lung tumor cells by regulating MicroRNA-144

    Oncology Research Editorial Office

    Oncology Research, Vol.32, No.11, pp. 1825-1825, 2024, DOI:10.32604/or.2024.056897 - 16 October 2024

    Abstract This article has no abstract. More >

Displaying 1-10 on page 1 of 132. Per Page